HAE
Haemonetics Corporation81.11
+0.71+0.88%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
IVT sales refresh shifts momentum
Q&A peeled back IVT's turnaround playbook: 60% of vascular closure reps in role under six months, closing gaps versus aggressive rivals while eyeing ASCs and MVP XL label expansion. Plasma's 20% organic surge split evenly between share grabs—direct and customer-enabled—and double-digit collections, with Ig demand signaling durability into FY27. Management was direct on PFA headwinds lapping and OEM leveling in SavvyWire. Margins get smaller boosts ahead. Sales force is punching back. Watch IVT stabilization and plasma volumes.
Key Stats
Market Cap
3.91BP/E (TTM)
23.72Basic EPS (TTM)
3.42Dividend Yield
0%Recent Filings
8-K
Published responsibility report
8-K
Q3 revenue down, margins up
Haemonetics reported Q3 fiscal 2026 revenue of $339M, down 2.7% reported but up 7.5% organic ex-CSL, with gross margin expanding to 59.7% from portfolio shifts and innovation. Plasma grew 3.5% while Blood Center plunged 19.6% post-Whole Blood divestiture; adjusted EPS hit $1.31, up 10%. Cash flow soared. Raised FY26 adjusted EPS to $4.90–$5.00 and free cash flow to $200M–$220M.
10-Q
Q3 FY2026 results
Haemonetics posted Q3 FY2026 revenues of $339M, down 2.7% y/y yet lifted by 3.5% Plasma growth amid U.S. collections strength, while Blood Center fell 19.6% y/y post-Whole Blood divestiture. Gross margins expanded to 59.7% from 55.5%, fueling 14% y/y operating income jump to $67M; diluted EPS rose 28% to $0.95 on 47M shares, consistent with net income. Cash swelled to $363M with $222M nine-month OCF minus $15M capex; total debt steady at $1.2B including $1B convertibles (2026/2029) and $241M term loan at 5.8%, revolver fully available sans covenants breach. Vivasure closed Jan 2026 for $116M upfront (cash), adding vessel closure to Hospital. Share buybacks trimmed shares 7% y/y. Patent suits with Terumo/Fresenius pose IP risks.
8-K
Acquires Vivasure for €100M
Haemonetics announced its acquisition of Vivasure Medical on January 9, 2026, buying all equity for €100 million upfront—€52 million net of prior investments and adjustments—plus up to €85 million contingent on sales growth and milestones, funded by cash on hand. The deal adds Vivasure's PerQseal Elite vessel closure tech, CE Mark-approved in Europe with FDA PMA submitted, targeting structural heart procedures. It bolsters Haemonetics' large-bore closure presence. Contingent payments hinge on milestones.
BSX
Boston Scientific Corporation
92.95+0.76
CERS
Cerus Corporation
2.16+0.15
ENOV
Enovis Corporation
26.07-0.47
EW
Edwards Lifesciences Corporatio
85.32+1.94
IRIX
IRIDEX Corporation
1.00+0.02
LMAT
LeMaitre Vascular, Inc.
83.41+0.64
MASI
Masimo Corporation
134.52-2.88
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NVNO
enVVeno Medical Corporation
0.32+0.01
SSMXF
Sysmex Corp.
9.33+0.00